SPECIFICITY STUDIES OF HIV AND HTLV PROTEASES

HIV 和 HTLV 蛋白酶的特异性研究

• 批准号: 2871217
• 负责人: Irene T Weber
• 金额: $ 3.89万
• 依托单位: THOMAS JEFFERSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-01 至 2002-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2871217
• 关键词: aspartic endopeptidases; drug resistance; human T cell lymphotropic virus type 1; human immunodeficiency virus 1; mutant; protease inhibitor; protein structure function; virus protein

Description: (Adapted from the Applicant's Abstract) The proposal's short-term aim is to eludicate the molecular basis for the action of resistant variants of Human Immunodeficiency Virus 1 (HIV-1) protease by comparing the structures and activities of selected mutants of HIV-1 and Rous sarcoma virus proteases. The specificity studies proposed will be: 1) to cover a broader set of oligopeptide substrates in order to more fully characterize the inhibitor-resistant HIV-1 protease mutants; and 2) promote new studies on the molecular basis for the specificity of the related human T-cell leukemia virus type 1 (HTLV-1) protease. The long-term aim is to predict new protease inhibitors and therapeutic strategies to overcome the problem of drug-resistance.

描述：（改编自申请人摘要）该提案是短期的 其目的是阐明耐药变异体作用的分子基础， 通过比较人免疫缺陷病毒1（HIV-1）蛋白酶的结构和 HIV-1和劳斯肉瘤病毒蛋白酶的选定突变体的活性。的 建议的特异性研究将：1）涵盖更广泛的寡肽组 为了更全面地表征耐药HIV-1 蛋白酶突变体;和2）促进新的研究的分子基础上， 相关人类T细胞白血病病毒1型（HTLV-1）的特异性 蛋白酶长期目标是预测新的蛋白酶抑制剂， 克服耐药性问题的治疗策略。